Basilea Pharmaceutica Ltd of Switzerland has appointed David Veitch as its chief commercial officer effective 1 September to oversee the commercialisation of its new products including a broad-spectrum antibiotic. Mr Veitch was most recently president of European operations at the former Savient Pharmaceuticals. Prior to that he held several positions at Bristol-Myers Squibb UK and Europe culminating in the job of senior vice president for marketing and brand commercialization in Europe, the Middle East and Asia.
Mr Veitch holds a Bachelor of Science degree in biology from the University of Bristol in the UK.
Basilea announced the appointment on 18 August 2014.
Copyright 2014 Evernow Publishing Ltd